Sara Klein, APRN
Acute Care · Lincoln, NENPI 1629082664
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $628 of the $702 with a category attached, or 89.5%. 9 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 35.3% of the total. Reporting peaked in 2023 at $235 and has fallen 91.7% since, to $20 in 2025.
Across 24 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$248
- Aurinia Pharma U.S., Inc.$149
- Boehringer Ingelheim$100
- AstraZeneca$74
- Mallinckrodt Hospital Products Inc.$74
- Bayer$16
- plus $41 from 3 others
What the payments were for
- Food & beverage$62889%
- Education$7411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 9 | $248 |
| Aurinia Pharma U.S., Inc. | 5 | $149 |
| Boehringer Ingelheim | 3 | $100 |
| AstraZeneca | 2 | $74 |
| Mallinckrodt Hospital Products Inc. | 1 | $74 |
| Bayer | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Velphoro$118
How this compares
$702 in reported general payments places this provider in the 65th percentile of 103 acute care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RenvelaSevelamer Carbonate | 17 | $14,259 |
| Sevelamer Carbonate | 61 | $4,847 |
| ClinisolParenteral Amino Acid 15% No.5 | 14 | $1,585 |
| Midodrine Hcl | 34 | $1,392 |
| Calcium Acetate | 29 | $1,356 |
| Torsemide | 17 | $401 |
| Rosuvastatin Calcium | 23 | $266 |
| Carvedilol | 37 | $243 |
| Metoprolol Succinate | 15 | $201 |
| Furosemide | 30 | $181 |
| Amlodipine Besylate | 35 | $180 |
| Allopurinol | 27 | $157 |
| Clonidine Hcl | 12 | $143 |
| Losartan Potassium | 25 | $128 |
| Hydralazine Hcl | 24 | $90 |
Paid to pharmacies, not to this prescriber.
Other acute care in Lincoln
- William SaalfeldLincoln$115K
- Sarah SchroederLincoln$6K
- Vicki NortonLincoln$3K
- Beth BreyLincoln$2K
- Simone MartinLincoln$2K
- Sarah Eckles van HornLincoln$2K
- Amanda HallLincoln$2K
- Megan StittLincoln$1K
- Beth CuetoLincoln$1K
- Cassandra MuellerLincoln$613
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.